In letrozole-resistant breast cancer cells, HIF-1α expression remains constitutively elevated through the HER2–PI3K/Akt/mTOR pathway, driving downstream targets such as BCRP that sustain resistance phenotypes [32]. Here, ERBB2 is linked to breast cancer.